 The update comes as Pfizer emerges as among the leaders in the race to develop the first Covid-19 vaccine. On Monday night, the company announced that its program had hit a new milestone, saying it had begun a Phase 23 study of its experimental vaccine. Mizuho analyst Vamil Divan wrote Tuesday that he expected shares of Pfizer to rise on the earnings news. 